← All companies
Psychedelic drug developers
Helus Pharma
Nasdaq: HELP · formerly Cybin · Toronto, Canada
$8.87
+0.11% (+$0.01) on the day
Close Nov 13, 2026
Market cap
$648M
1 month
−19.73%
52-week range
$3.76–$15.15
Last month
Why we cover it
Formerly Cybin, renamed in January 2026 when it moved from NYSE American to Nasdaq. Its lead drug, a psilocybin-derived compound, is in Phase 3 for depression, and it holds more than 100 granted patents.
Financials
Recent financials aren't available in a standard format for this company. See its SEC filings ↗
Clinical trials Trials tracker
| Trial | Compound | Stage |
|---|---|---|
| HLP003 for Major Depressive Disorder | Psilocybin | Phase 3 (enrollment complete) |
Patents Patent tracker
| Holder | Compounds | Granted | Pending | Expire |
|---|---|---|---|---|
| Small Pharma Ltd | DMT, 5-MeO-DMT, Ketamine | 6 | 16 | 2040–2042 |
| Cybin UK Ltd | DMT, 5-MeO-DMT | 6 | 4 | 2040–2043 |
News (1)
In the Journal (6)
- Sep 29, 2026 Only 3 of 10 Psychedelic Companies Lobby Washington. One Just Joined — Twice, in the Same Quarter.
- Sep 23, 2026 Which Psychedelic-Company CEO's Pay Actually Matched Their Stock's Performance? We Checked All 10 — Almost None Did.
- Sep 21, 2026 19% of American Adults Have Anxiety. Every Drug Treating It Is a Decades-Old Generic — Here's Who Wins If DT120 Changes That
- Sep 17, 2026 The Psychedelic Money Graveyard: Renames, Reverse Mergers, and the Companies That Didn't Make It
- Sep 11, 2026 The Psychedelic Money Rankings: $11 Billion Public, $1.6 Billion Private, $140 Million From Governments
- Aug 24, 2026 The 5-MeO-DMT Patent Race Has a Twist: The Clinical Leader Barely Owns Any of It
Prices are end-of-day closes from Nasdaq; financials come from SEC filings. Not investment advice.